Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Pfizer’s COVID-19 Booster Now in Line for Approval for Age 18-Plus
Pfizer’s COVID-19 vaccine Comirnaty cleared a review by a health ministry advisory panel on November 10 for its label expansion to include use for booster vaccinations, putting it in line for approval as early as November 11. The Pharmaceutical Affairs…
To read the full story
Related Article
- Japan Secures 18 Million Extra Doses of Moderna Vaccines
December 27, 2021
- Moderna COVID-19 Booster to Start from December 17
December 17, 2021
- Japan Approves Moderna Vaccine for COVID-19 Booster
December 16, 2021
- Japan Panel OKs Moderna COVID-19 Vaccine for Booster Use
December 16, 2021
- Moderna COVID-19 Booster Up for Panel Review on Dec. 15
December 9, 2021
- Shorter Booster Interval for All Citizens Difficult: Health Minister
December 8, 2021
- Health Minister Stresses Basic 8-Month Interval for Booster Shot
November 17, 2021
- Japan to Use mRNA Jabs for Boosters, Pfizer Vaccine for Time Being: Panel
November 16, 2021
- Japan Approves Pfizer COVID-19 Vaccine for Booster Use
November 11, 2021
- Pfizer’s COVID-19 Booster Up for PAFSC Review on Nov. 10
November 5, 2021
- Booster Shots to Start with Pfizer Vaccine: MHLW
November 2, 2021
- Japan Panel OKs Booster Shots for All People Who Took 2 Doses
October 29, 2021
- Govt to Deliver 4.12 Million Comirnaty Doses for COVID-19 Boosters: Minister
October 19, 2021
- Japan Clinches Deal for 120 Million Extra Pfizer Vaccine Doses
October 8, 2021
- MHLW Eyes Booster Shots for Healthcare Workers from December
September 24, 2021
- Japan Needs Setups to Execute Booster Shots by Year-End: Minister
September 22, 2021
- MHLW to Promptly Seek Expert Panel Discussion on Booster Shots: Minister
September 13, 2021
- Japan Should Arrange Boosters Immediately, Mix-and-Match Doses Too: LDP
September 10, 2021
- Japan Secures Enough Doses for Booster Shots Next Year: Minister
August 18, 2021
REGULATORY
- Celltrion’s Eylea Biosimilar Nears Approval, but Listing Outlook Clouded
February 27, 2026
- Japan Panel to Review Joenja, Dojolvi for Approval at March 5 Session
February 27, 2026
- Japan to Closely Monitor US “MFN” Policy: PM Takaichi
February 27, 2026
- Japan to Update Adult Pneumococcal Fact Sheet Ahead of Capvaxive NIP Review
February 27, 2026
- Takaichi Signals Continued Off-Year Revisions despite Abolition Calls
February 26, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…